Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimethyl ampal thiolester (DIMATE) is a **small molecule inhibitor** of aldehyde dehydrogenases, specifically targeting ALDH1 and ALDH3 isoforms. It acts as a competitive, irreversible inhibitor of ALDH1, displaying major cytotoxic activity against human acute myeloid leukemia (AML) cell lines, particularly those enriched in leukemia stem cells (LSCs). Unlike conventional chemotherapy, DIMATE selectively eradicates AML LSCs while sparing healthy hematopoietic stem cells. This selectivity positions DIMATE as a promising novel agent for AML. It is under investigation for use in AML and related hematologic malignancies[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimethyl ampal thiolester.